Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. 2009

Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Turkey. ismailsari35@gmail.com

OBJECTIVE Endothelial dysfunction is present in ankylosing spondylitis (AS). However, the etiology of events is still unclear. The aim of the present study was to investigate whether there are abnormalities in nitric oxide (NO) metabolism and endothelin-1 (ET-1) in AS patients. METHODS Subjects without any classical cardiovascular (CV) risk factors were studied. Fasting glucose, serum lipids, high sensitive CRP (hsCRP), ESR, asymmetric dimethylarginine (ADMA) and ET-1 were studied. Patients were also evaluated with the Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index, and the Bath Ankylosing Spondylitis Disease Activity Index. RESULTS A total of 48 AS patients (38.6+/-10.6 years; 36M/12F) and 38 controls (36.4+/-11.1 years; 27M/11F) were studied. Acute phase reactants including hsCRP, and ESR were significantly increased in the patients group (p<0.05). Serum ADMA concentrations were also significantly higher in AS than in controls. Plasma levels of ET-1 did not differ between the groups (p>0.05). Comparison of three groups (conventional and anti-TNF treatment groups and controls) revealed that ADMA was significantly higher in the conventional treated AS than in controls. The levels of ADMA were not different between anti-TNF group and healthy subjects. Plasma ET-1 concentrations were similar between groups (p>0.05). Correlation analysis yielded significant correlations between ADMA, hsCRP, LDL cholesterol, HDL cholesterol and triglycerides (p<0.05). CONCLUSIONS The increased ADMA levels obtained in a group of relatively young AS patients who did not have classical CV risk factors suggest that NO metabolism is impaired in AS. On the other hand, anti-TNF treatments may have a beneficial effect on vascular function in AS.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013167 Spondylitis, Ankylosing A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions. Ankylosing Spondylitis,Bechterew Disease,Marie-Struempell Disease,Rheumatoid Spondylitis,Spondylarthritis Ankylopoietica,Ankylosing Spondylarthritis,Ankylosing Spondyloarthritis,Bechterew's Disease,Spondylitis Ankylopoietica,Spondyloarthritis Ankylopoietica,Ankylosing Spondylarthritides,Ankylosing Spondyloarthritides,Bechterews Disease,Marie Struempell Disease,Spondylarthritides, Ankylosing,Spondylarthritis, Ankylosing,Spondylitis, Rheumatoid,Spondyloarthritides, Ankylosing,Spondyloarthritis, Ankylosing
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
March 2011, Joint bone spine,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
January 2011, Clinical rheumatology,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
February 2014, Inflammation,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
January 2008, Clinical chemistry and laboratory medicine,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
February 2017, International journal of rheumatic diseases,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
March 2017, Kidney international reports,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
January 2013, Clinical and experimental rheumatology,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
November 2012, Journal of inherited metabolic disease,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
January 2011, Journal of atherosclerosis and thrombosis,
Ismail Sari, and Levent Kebapcilar, and Ahmet Alacacioglu, and Oktay Bilgir, and Yasar Yildiz, and Ali Taylan, and Arif Yuksel, and Didem L Kozaci
January 2011, Disease markers,
Copied contents to your clipboard!